companydata.dkcompanydata.dk

UNION therapeutics A/S: Financial statements 2025

CVR: 33963750

Source: annual report 2025, Danish Business Authority

01/01/2025 – 31/12/2025

UNION therapeutics A/S (CVR 33963750) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -11,802,644 and a net result of DKK -32,142,051 compared with DKK -98,922,000 the year before. Equity in the 2025 report amounted to DKK -147,650,138. The company had 8 employees in the financial year.

Gross Profit
DKK -11,802,644
Profit/Loss
DKK -32,142,051
Equity
DKK -147,650,138
Total Assets
DKK 29,361,497
Employees
8

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2025--11.8M-32.1M-147.7M8
2024621K--98.9M-150.1M-
20232.3M--169.4M-61.6M-
202234.4M--214.3M-27.7M-
2021118.9M--56M49.4M26

Official annual report

View the official annual report directly on the page with a Pro subscription.

How creditworthy is UNION therapeutics A/S?

See the CDS score and get a full credit report with recommended credit limit and payment terms.

Read about the CDS score

Events in 2025

Morten Højland Boesen steps down as director of UNION therapeutics A/SNov 28, 2025

As of November 28, 2025, Morten Højland Boesen has stepped down as director of UNION therapeutics A/S.

UNION therapeutics A/S: The 2024 annual report is outMar 28, 2025

UNION therapeutics A/S has published its annual report for 2024. Revenue came to DKK 621,000, and the net result was DKK -98,922,000.

Gitte Pugholm Aabo leaves the board of UNION therapeutics A/SMar 26, 2025

As of March 26, 2025, Gitte Pugholm Aabo has left the board of directors of UNION therapeutics A/S.

Arthur Joseph Higgins leaves the board of UNION therapeutics A/SMar 26, 2025

As of March 26, 2025, Arthur Joseph Higgins has left the board of directors of UNION therapeutics A/S.

About UNION therapeutics A/S

UNION therapeutics A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2011. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named AntibioTx A/S and ANTIBIOTX ApS. The management consists of Kim Domela Kjøller, Morten Otto Alexander Sommer and Rasmus Vendler Toft-Kehler. The board consists of Stig Løkke Pedersen (chair), Andrew John Oakley, Morten Otto Alexander Sommer and Peter Kristensen. The company's owners include MANJIN ApS, VENDLER ApS and T&W HOLDING A/S. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK -11,802,644 and a net result of DKK -32,142,051 compared with DKK -98,922,000 the year before. Equity in the 2025 report amounted to DKK -147,650,138.

Source: annual report 2025, Danish Business Authority